Viveve Medical, Inc. (NASDAQ:VIVE) has been given a $11.00 target price by investment analysts at Cowen and Company in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the stock. Cowen and Company’s price target indicates a potential upside of 91.97% from the stock’s previous close.

VIVE has been the subject of a number of other research reports. ValuEngine raised shares of Viveve Medical from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Viveve Medical in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $10.50.

Shares of Viveve Medical (NASDAQ VIVE) traded down 1.5497% during midday trading on Monday, reaching $5.6412. The company’s stock had a trading volume of 146,527 shares. The firm’s market capitalization is $109.47 million. Viveve Medical has a 12-month low of $3.75 and a 12-month high of $11.16. The stock has a 50-day moving average of $5.49 and a 200 day moving average of $6.66.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings data on Thursday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.21). Viveve Medical had a negative net margin of 266.93% and a negative return on equity of 244.96%. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.24 million. During the same period in the previous year, the firm posted ($0.66) EPS. The firm’s quarterly revenue was up 97.4% on a year-over-year basis. Equities research analysts predict that Viveve Medical will post ($1.94) EPS for the current fiscal year.

WARNING: “Viveve Medical, Inc. (VIVE) Given a $11.00 Price Target at Cowen and Company” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/24/viveve-medical-inc-vive-given-a-11-00-price-target-at-cowen-and-company.html.

In other news, CFO Scott Durbin bought 5,000 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were bought at an average cost of $5.25 per share, for a total transaction of $26,250.00. Following the acquisition, the chief financial officer now directly owns 11,568 shares of the company’s stock, valued at approximately $60,732. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 35.10% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. HighTower Advisors LLC lifted its holdings in shares of Viveve Medical by 33.2% in the 2nd quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock worth $12,379,000 after acquiring an additional 430,033 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Viveve Medical by 135.4% in the 2nd quarter. Vanguard Group Inc. now owns 450,142 shares of the company’s stock worth $3,232,000 after acquiring an additional 258,912 shares during the last quarter. Manatuck Hill Partners LLC lifted its holdings in shares of Viveve Medical by 128.6% in the 2nd quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock worth $2,872,000 after acquiring an additional 225,000 shares during the last quarter. State Street Corp acquired a new position in shares of Viveve Medical in the 2nd quarter worth approximately $1,282,000. Finally, ING Groep NV acquired a new position in shares of Viveve Medical in the 2nd quarter worth approximately $1,205,000. Hedge funds and other institutional investors own 65.56% of the company’s stock.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.